相关实验视频

Updated: Jun 5, 2025

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

治疗点分子在食管胃结和巴雷特腺癌中的表达

Hiroyuki Abe¹, Masayuki Urabe^2,3, Koichi Yagi²

¹Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. hiabe-tky@g.ecc.u-tokyo.ac.jp.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

|December 11, 2024

概括

大多数食管胃结和巴雷特腺癌有资格接受分子向治疗. PD-L1表达 (CPS ≥1) 与更好的生存率有关,指导这些癌症的精确医学.

科学领域:

胃肠病学胃肠病学
在瘤学瘤学.
分子病理学分子病理学

背景情况:

新的分子向疗法正在出现,用于胃和食道腺癌.
这项研究调查了食管胃结 (EGJ) 和巴雷特腺癌中的治疗分子状态.

研究的目的:

评估EGJ和巴雷特腺癌中关键分子标的表达.
为了将目标分子表达与患者生存结果相关联.
为了确定这些癌症类型的分子向治疗的资格.

主要方法:

分析了来自114个EGJ和30个巴雷特腺癌的组织微阵列.
对不匹配修复蛋白,PD-L1,HER2,CLDN18,FGFR2b和EBER-ISH进行了免疫组织化学检查.
在模两可的情况下,通过现场杂交评估HER2基因放大.

主要成果:

观察到高的目标分子表达率:PD-L1 (61.4%的EGJ,76.7%的巴雷特),CLDN18 (33.3%的EGJ,23.3%的巴雷特) 和HER2 (9.6%的EGJ,20%的巴雷特).
PD-L1表达 (组合阳性得分[CPS] ≥1) 与明显更长的无复发和整体存活相关.
超过80%的EGJ和巴雷特腺癌表达至少一个点分子.

结论:

大多数食管胃结和巴雷特腺癌都显示出对分子向治疗的潜在资格.
使用分子测试进行患者分层化对于在这些癌症中实施精准医学至关重要.
PD-L1表达作为治疗反应和生存的潜在预测生物标志物.

关键词:

在 CLDN18 中.消化道 - 胃结口 FGFR2bb 的意思是什么?在HER2中,HER2是HER2.在PD-L1中.

更多相关视频

Subculture and Cryopreservation of Esophageal Adenocarcinoma Organoids: Pros and Cons for Single Cell Digestion

Subculture and Cryopreservation of Esophageal Adenocarcinoma Organoids: Pros and Cons for Single Cell Digestion

Published on: July 6, 2022

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

相关概念视频

Barrett Esophagus-II: Clinical Manifestations and Management

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...

Barrett Esophagus-I: Introduction

Barrett Esophagus-I: Introduction

Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.